AK2 and hepatocellular carcinoma: To determine the contribution of the reinforced BRAF/MAPK to the formation of HCC in AK2-deficient mice, we examined antitumor effects of multi-kinase inhibitor, Sorafenib, which had been shown to also inhibit BRAF.